MiNK Therapeutics, Inc. (INKT) Earnings Call Transcripts

MiNK Therapeutics, Inc.'s Latest Earnings Call - Q1 FY2026

MiNK Therapeutics, Inc. reported its Q1 2026 earnings, highlighting significant progress in its clinical programs. The company ended the quarter with a cash balance of $9.5 million, after raising $3 million through aftermarket sales. The net loss for the quarter was $2.7 million or $0.57 per share, slightly improved from the previous year's $2.8 million loss. Management emphasized the initiation of a randomized Phase II trial for agenT-797 in ARDS, with expected data readouts in the second half of 2026. No specific revenue or earnings guidance changes were provided, but the company maintains a cash runway for at least 12 months.

Reported metrics

Guidance from management

Management expects to present preliminary data from the randomized Phase II trial for agenT-797 in ARDS in the second half of 2026. The cash position is expected to support operations for at least 12 months.

What analysts pressed on

Analysts questioned the patient enrollment numbers and endpoints for the ARDS trial, as well as the details of the ImmunityBio collaboration. Concerns were raised about the ability to predict patient response using biomarkers and the commercial strategy for the ARDS program.

Main topics on the call

• Clinical Trial Progress — MiNK announced the initiation of a randomized Phase II trial for agenT-797 in ARDS, with a 1:1 randomization of 90 patients. Management expects to present preliminary findings in the second half of 2026. "We believe that...
• Scientific Presentations — The company presented data at several scientific conferences, highlighting the versatility of its iNKT cell therapy across different disease settings. "The same donor-derived product manufactured through our GMV process,...
• Financial Position — MiNK ended Q1 2026 with $9.5 million in cash, after raising $3 million and repaying $5.2 million in convertible notes. The company expects its cash position to support operations for at least 12 months.
• Collaboration and Partnerships — MiNK highlighted its collaboration with ImmunityBio for a combination therapy targeting fungal pneumonia, emphasizing the growing unmet need in this area. "This case amplifies the observations we've seen was a case of im...

Read the full MiNK Therapeutics, Inc. transcript (Q1 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 18 MiNK Therapeutics, Inc. earnings call transcripts on record, spanning August 9, 2022 to August 13, 2026. Based on this history, MiNK Therapeutics, Inc. reports quarterly. The most recent call on file is dated August 13, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

INKT

Exchange

NasdaqCM

Country

US

Sector

Health Care

Industry

Biotechnology

Calls on record

18

First call

August 9, 2022

Most recent

August 13, 2026

Reporting cadence

quarterly